Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note

Pfizer (PFE) closed the most recent trading day at $25.57, moving -3.27% from the previous trading session. This change lagged the S&P 500's 0.24% loss on the day. Meanwhile, the Dow lost 0.62%, and the Nasdaq, a tech-heavy index, added 0.23%. Shares of the drugmaker witnessed a gain of 5.38% over the previous month, beating the performance of the Medical sector with its gain of 2.79%, and the S&P 500's gain of 1.31%.Market participants will be closely following the financial results of Pfizer in its upcoming release. It is anticipated that the company will report an EPS of $0.61, marking a 3.17% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $18 billion, indicating a 1.33% upward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.13 per share and revenue of $62.85 billion. These totals would mark changes of +0.64% and -1.23%, respectively, from last year. Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Pfizer currently has a Zacks Rank of #3 (Hold). In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.44. This signifies a discount in comparison to the average Forward P/E of 14.11 for its industry. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 198, this industry ranks in the bottom 20% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Naming Top 10 Stocks for 2026Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks